Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.18 USD | +3.25% | +4.26% | -18.04% |
Apr. 18 | Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board | CI |
Mar. 12 | Anixa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024 | CI |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 101M |
---|---|---|---|---|---|
Net income 2024 * | -14M | Net income 2025 * | -15M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-7.23
x | P/E ratio 2025 * |
-7.07
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.1% |
Latest transcript on Anixa Biosciences, Inc.
1 day | +3.25% | ||
1 week | +4.26% | ||
Current month | +1.92% | ||
1 month | -8.09% | ||
3 months | -33.47% | ||
6 months | +3.25% | ||
Current year | -18.04% |
Managers | Title | Age | Since |
---|---|---|---|
Amit Kumar
CEO | Chief Executive Officer | 59 | 12-10-31 |
Michael Catelani
DFI | Director of Finance/CFO | 57 | 16-10-31 |
Pamela Garzone
PRN | Corporate Officer/Principal | 69 | 21-09-06 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lewis Titterton
BRD | Director/Board Member | 79 | 99-06-30 |
Amit Kumar
CEO | Chief Executive Officer | 59 | 12-10-31 |
Emily Gottschalk
BRD | Director/Board Member | 63 | 19-10-22 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 3.18 | +3.58% | 357,353 |
24-04-23 | 3.07 | +1.99% | 73,542 |
24-04-22 | 3.01 | -3.53% | 57,975 |
24-04-19 | 3.12 | +0.65% | 32,692 |
24-04-18 | 3.1 | +1.64% | 58,503 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.04% | 101M | |
+4.09% | 43.84B | |
+46.11% | 41.25B | |
+9.45% | 41.68B | |
-10.92% | 27.04B | |
+9.32% | 25.53B | |
-24.87% | 18.18B | |
+29.70% | 12.29B | |
+1.28% | 12.29B | |
+7.78% | 11.15B |
- Stock Market
- Equities
- ANIX Stock